Paclitaxel-Eluting Coronary Stent

A paclitaxel-eluting coronary stent system incorporates a next-generation stent with highly flexible cell geometry, thin struts, and uniform cell distribution.

Called Taxus Liberte, the stent is the product of Boston Scientific corp. (Natick, MA, USA) and features the Veriflex design. This new platform offers better delivery and conformity in challenging anatomy. It also features the enhanced TrakTip catheter tip, mounted on the delivery catheter, which provides better lesion crossability. In addition, TrakTip has a low lesion-entry profile, which further improves crossability. The Taxus Liberte is now being marketed in 18 countries around the world.

"My experience with the Liberte system demonstrates that it represents a dramatic step forward in stent technology,” commented John Ormiston, M.D., interventional cardiologist at Mercy Hospital and Auckland City Hospital (New Zealand). "Its ability to conform to the vessel wall is outstanding, and its ease of deliverability allows us to more easily reach some of the difficult lesions.”

Boston Scientific has announced enrollment in a clinical trial designed to support approval of the stent system by the U.S. Food and Drug Administration (FDA). The company's first-generation drug-eluting stent system, the Taxus Express2 paclitaxel-eluting coronary stent system, is the leader of the worldwide coronary stent market.





Related Links:
Boston Scientific